Milena Pavlova, MD
Epilepsy · Boston, MANPI 1043276306
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 73.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $9,594 and has fallen 51.8% since, to $4,626 in 2025.
Across 28 payments — averaging $830.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$17K
- Sanofi$3K
- Pear Therapeutics (US), Inc.$2K
- Biogen$910
- Harmony Biosciences LLC$223
- ZOLL Respicardia, Inc.$181
- plus $232 from 4 others
Across 5 payments — averaging $22,491 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$99K
- Lundbeck LLC$13K
What the payments were for
- Consulting fees$12,86655%
- Speaking & faculty fees$8,30236%
- Travel & lodging$8294%
- Food & beverage$1,1485%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 15 | $17,184 |
| Sanofi | 1 | $2,820 |
| Pear Therapeutics (US), Inc. | 1 | $1,700 |
| Biogen | 2 | $910 |
| Harmony Biosciences LLC | 2 | $223 |
| ZOLL Respicardia, Inc. | 1 | $181 |
| Idorsia Pharmaceuticals US Inc | 2 | $113 |
| Livanova USA, Inc. | 1 | $65 |
| UCB, Inc. | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,250 in reported general payments places this provider in the 85th percentile of 28 epilepsy providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rufinamide | 13 | $2,516 |
| Lamotrigine | 23 | $1,000 |
| Eszopiclone | 20 | $644 |
| Gabapentin | 17 | $249 |
| Trazodone Hcl | 18 | $205 |
| Pregabalin | 13 | $92 |
| Clonazepam | 21 | $59 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Boston
- Andrew ColeBoston$186K
- Claire JacobsBoston$118K
- Ioannis KarakisBoston$56K
- Alice LamBoston$10K
- Rani SarkisBoston$6K
- Paula VoinescuBoston$5K
- Peter HadarBoston$413
- Niravkumar BarotBoston$352
- Ronald ThibertBoston$304
- Christopher McGrawBoston$294
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.